Search

Displaying results 5371 - 5380 of 7186 in total
  1. Drug

    LU-31130

    go.drugbank.com/drugs/DB05828
    Experimental

    LU-31130 is a rapid acting therapy developed by H. Lundbeck A/S to treat Psychosis, Schizophrenia and Schizoaffective Disorders.

  2. Drug

    anti-alpha5Beta1-integrin antibody

    go.drugbank.com/drugs/DB05870
    Experimental

    The integrin alpha5beta1 has been shown to play a critical role during angiogenesis. anti-alpha5beta1 integrin antibody inhibits angiogenesis, including vessel formation induced by vascular endothelial

  3. Drug

    Arsthinol

    go.drugbank.com/drugs/DB08928
    Experimental

    Considered well tolerated when compared to other related trivalent organoarsenicals, arsthinol has even undergone recent studies as a potential anticancer agent. … Arsthinol (INN) is an antiprotozoal agent that was first synthesized by Ernst A.H. Friedheim in 1949 via the complexing of acetarsol with 2,3-dimercaptopropanol.

  4. Drug

    Xanthine

    go.drugbank.com/drugs/DB02134
    Investigational

    It is an intermediate in the degradation of adenosine monophosphate to uric acid, being formed by oxidation of hypoxanthine.

  5. Drug

    Granisetron

    go.drugbank.com/drugs/DB00889
    ApprovedInvestigational

    A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  6. Drug

    Sifalimumab

    go.drugbank.com/drugs/DB12773
    Investigational

    Sifalimumab may suppress the abnormal immune activity associated with lupus by binding to multiple interferon-alpha subtypes seen in the serum of lupus patients.

  7. Drug

    Brofaromine

    go.drugbank.com/drugs/DB13876
    Experimental

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  8. Drug

    2,5-Dimethoxy-4-ethylthioamphetamine

    go.drugbank.com/drugs/DB13940
    Experimental

    2,5-Dimethoxy-4-ethylthioamphetamine (ALEPH-2) is a phenylisopropylamine derivative with alleged anxiolytic and hallucinogenic properties.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  9. Drug

    SR 140333

    go.drugbank.com/drugs/DB05790
    Experimental

    SR 140333 is tachykinin antagonist which has potential to treat diarrhoea due to food allergy or inflammatory bowel disease.

  10. Drug

    CHGN111

    go.drugbank.com/drugs/DB06376
    Experimental

    CHGN111 is an inhibitor of the mitochondrial enzyme CLK-1 which is a demethoxyubiquinone hydroxylase. Numerous parameters of mitochondrial function are altered when the activity of CLK-1 is reduced, which results in a decrease of ROS at ...